Beam Therapeutics Secures $500 Million Financing Facility With Sixth Street

Reuters
02/24
Beam <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Secures $500 Million Financing Facility With Sixth Street

Beam Therapeutics Inc. entered a $500 million senior secured credit facility with Sixth Street to support the potential launch of its sickle cell disease therapy risto-cel. The facility includes $100 million funded at closing, up to $300 million available upon specified clinical, regulatory and commercial milestones, and an additional $100 million available at Beam’s option subject to mutual agreement. The seven-year facility matures in early 2033, carries an interest rate of about 10% based on current SOFR projections, has no scheduled amortization, and is secured by first-priority liens on substantially all of Beam’s assets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602240700PRIMZONEFULLFEED9659424) on February 24, 2026, and is solely responsible for the information contained therein.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10